Literature DB >> 26434644

Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications.

Jung Hoon Lee1, Yanxialei Jiang1, Yong Tae Kwon2, Min Jae Lee3.   

Abstract

The N-end rule pathway is a proteolytic system in which single N-terminal amino acids of short-lived substrates determine their metabolic half-lives. Substrates of this pathway have been implicated in the pathogenesis of many diseases, including malignancies, neurodegeneration, and cardiovascular disorders. This review provides a comprehensive overview of current knowledge about the mechanism and functions of the N-end rule pathway. Pharmacological strategies for the modulation of target substrate degradation are also reviewed, with emphasis on their in vivo implications. Given the rapid advances in structural and biochemical understanding of the recognition components (N-recognins) of the N-end rule pathway, small-molecule inhibitors and activating ligands of N-recognins emerge as therapeutic agents with novel mechanisms of action.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26434644      PMCID: PMC4641009          DOI: 10.1016/j.tips.2015.07.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  112 in total

Review 1.  The ubiquitin-proteasome pathway and pathogenesis of human diseases.

Authors:  A L Schwartz; A Ciechanover
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

2.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

3.  Small molecule inhibitors of arginyltransferase regulate arginylation-dependent protein degradation, cell motility, and angiogenesis.

Authors:  Sougata Saha; Junling Wang; Brian Buckley; Qingqing Wang; Brenda Lilly; Mikhail Chernov; Anna Kashina
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

4.  Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Authors:  Fleur Broekman; Elisa Giovannetti; Godefridus J Peters
Journal:  World J Clin Oncol       Date:  2011-02-10

5.  Universality and structure of the N-end rule.

Authors:  D K Gonda; A Bachmair; I Wünning; J W Tobias; W S Lane; A Varshavsky
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

Review 6.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

7.  Regional expression of RGS4 mRNA in human brain.

Authors:  Holly A Erdely; Robert A Lahti; Mary B Lopez; Carol S Myers; Rosalinda C Roberts; Carol A Tamminga; Michael W Vogel
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

8.  P-Chloramphetamine: Selective neurotoxic action in brain.

Authors:  J A Harvey; S E McMaster; L M Yunger
Journal:  Science       Date:  1975-03-07       Impact factor: 47.728

9.  A recognition component of the ubiquitin system is required for peptide transport in Saccharomyces cerevisiae.

Authors:  K Alagramam; F Naider; J M Becker
Journal:  Mol Microbiol       Date:  1995-01       Impact factor: 3.501

10.  A neurostimulant para-chloroamphetamine inhibits the arginylation branch of the N-end rule pathway.

Authors:  Yanxialei Jiang; Won Hoon Choi; Jung Hoon Lee; Dong Hoon Han; Ji Hyeon Kim; Young-Shin Chung; Se Hyun Kim; Min Jae Lee
Journal:  Sci Rep       Date:  2014-09-12       Impact factor: 4.379

View more
  8 in total

1.  N-terminal methionine excision of proteins creates tertiary destabilizing N-degrons of the Arg/N-end rule pathway.

Authors:  Kha The Nguyen; Jeong-Mok Kim; Sang-Eun Park; Cheol-Sang Hwang
Journal:  J Biol Chem       Date:  2019-01-23       Impact factor: 5.157

2.  The arginylation branch of the N-end rule pathway positively regulates cellular autophagic flux and clearance of proteotoxic proteins.

Authors:  Yanxialei Jiang; Jeeyoung Lee; Jung Hoon Lee; Joon Won Lee; Ji Hyeon Kim; Won Hoon Choi; Young Dong Yoo; Hyunjoo Cha-Molstad; Bo Yeon Kim; Yong Tae Kwon; Sue Ah Noh; Kwang Pyo Kim; Min Jae Lee
Journal:  Autophagy       Date:  2016-08-25       Impact factor: 16.016

3.  The Antipsychotic Drug Clozapine Suppresses the RGS4 Polyubiquitylation and Proteasomal Degradation Mediated by the Arg/N-Degron Pathway.

Authors:  Jun Hyoung Jeon; Tae Rim Oh; Seoyoung Park; Sunghoo Huh; Ji Hyeon Kim; Binh Khanh Mai; Jung Hoon Lee; Se Hyun Kim; Min Jae Lee
Journal:  Neurotherapeutics       Date:  2021-04-21       Impact factor: 6.088

4.  Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro.

Authors:  Seung Kyun Shin; Ji Hyeon Kim; Jung Hoon Lee; Young Hoon Son; Min Wook Lee; Hak Joong Kim; Sue Ah Noh; Kwang Pyo Kim; In-Gyu Kim; Min Jae Lee
Journal:  Exp Mol Med       Date:  2017-01-20       Impact factor: 8.718

Review 5.  Control of protein degradation by N-terminal acetylation and the N-end rule pathway.

Authors:  Kha The Nguyen; Sang-Hyeon Mun; Chang-Seok Lee; Cheol-Sang Hwang
Journal:  Exp Mol Med       Date:  2018-07-27       Impact factor: 8.718

6.  A modular degron library for synthetic circuits in mammalian cells.

Authors:  Hélène Chassin; Marius Müller; Marcel Tigges; Leo Scheller; Moritz Lang; Martin Fussenegger
Journal:  Nat Commun       Date:  2019-05-01       Impact factor: 14.919

Review 7.  N-Terminal Acetylation-Targeted N-End Rule Proteolytic System: The Ac/N-End Rule Pathway.

Authors:  Kang-Eun Lee; Ji-Eun Heo; Jeong-Mok Kim; Cheol-Sang Hwang
Journal:  Mol Cells       Date:  2016-02-16       Impact factor: 5.034

8.  Ablation of Arg-tRNA-protein transferases results in defective neural tube development.

Authors:  Eunkyoung Kim; Seonmu Kim; Jung Hoon Lee; Yong Tae Kwon; Min Jae Lee
Journal:  BMB Rep       Date:  2016-08       Impact factor: 4.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.